Protalix Biotherapeutics, Inc.
2 Snunit Street, Science Park
P.O. Box 455
Karmiel
21000
Tel: 972-4-988-9488
Fax: 972-4-988-9489
Website: http://www.protalix.com/
Email: info@protalix.com
292 articles about Protalix Biotherapeutics, Inc.
-
Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021
11/8/2021
Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the third quarter 2021 and provide a financial and business update on Monday, November 15, 2021.
-
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease
10/11/2021
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases provided a regulatory update regarding pegunigalsidase alfa for the proposed treatment of Fabry disease which included an announcement of the receipt of the official Type A meeting minutes from the U.S. FDA regarding the Complete Response Letter received for the PRX–102 Biologics License Application confirming a potential pathway for resubmission of a BLA for PRX–102.
-
Protalix BioTherapeutics Announces Closing of Private Note Exchange
8/26/2021
Protalix BioTherapeutics, Inc. today announced that it has completed exchanges (the "Exchanges") of the Company's outstanding 7.50% Senior Secured Convertible Notes due 2021 (the "2021 Notes") with institutional note holders of a substantial majority of the 2021 Notes.
-
Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update
8/16/2021
Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, reported financial results for the second quarter ended June 30, 2021 and provided a financial and business update.
-
Protalix BioTherapeutics Announces Private Note Exchange - Aug 13, 2021
8/13/2021
Protalix BioTherapeutics, Inc. announced the entry into definitive agreements relating to exchanges of an aggregate of $54.65 million principal amount of the Company's outstanding 7.50% Senior Secured Convertible Notes due 2021 for an aggregate of $28.75 million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024, $25.90 million in cash, and accrued and unpaid interest through the closing date.
-
Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021
8/9/2021
Company to host conference call and webcast at 8:30 a.m. EDT
-
Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA
8/2/2021
Protalix BioTherapeutics, Inc. announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration to discuss the Complete Response Letter dated April 27, 2021 regarding the Biologics License Application for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease.
-
Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021
6/28/2021
Protalix BioTherapeutics, Inc. announced that Dror Bashan, the Company's President and Chief Executive Officer along with Eyal Rubin, the Company's Chief Financial Officer, will participate in a fireside chat discussion hosted by Zacks Investment Research's John Vandermosten.
-
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease
6/2/2021
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthare Group, provided an update regarding the clinical development of pegunigalsidase alfa for the proposed treatment of Fabry disease.
-
Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update
5/14/2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the first quarter ended March 31, 2021
-
Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021
5/7/2021
Company to host conference call and webcast at 8:30 a.m. EDT
-
The U.S. FDA approved Chiesi Global Rare Diseases’ Ferriprox for treatment of transfusional iron overload caused by sickle cell disease (SCD) or other anemias in adults and children ages three years and older. This approval expands the use of the drug for patients with SCD or other anemias.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
4/28/2021
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced that they received a Complete Response Letter from the U.S. Food and Drug Administration regarding the Biologics License Application seeking accelerated approval of pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease.
-
Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA
4/28/2021
Protalix BioTherapeutics, Inc. today provided an update regarding the Complete Response Letter (CRL) received from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX–102) for the proposed treatment of adult patients with Fabry disease. Receipt of the CRL was announced earlier today.
-
The U.S. Food and Drug Administration’s schedule for April has several PDUFA dates scattered across the rest of the month. Here’s a look.
-
Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
3/30/2021
Successfully raised approximately $40 million in gross proceeds in an equity offering led by BofA Securities and Oppenheimer
-
Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
3/22/2021
Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, announced that it will release its financial results for fiscal year 2020 and business update on Tuesday, March 30, 2021.
-
Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
3/4/2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced today announced that the Company's management will participate and present a corporate overview at the H.C. Wainwright Global Life Sciences Conference,
-
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
-
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
2/18/2021
Anticipated PDUFA for PRX-102 in Fabry disease currently set for April 27, 2021 Company, with its Commercialization Partner, Chiesi, poised to commercialize PRX-102 Additional data and milestones expected throughout 2021